Experimental study of radioimmunotherapy versus chemotherapy for colorectal cancer

British Journal of Surgery

Volumn 98, Issue 3, 2011, Pages 436-441

  De Jong, G M ^a   Bleichrodt, R P ^a   Eek, A ^a   Oyen, W J G ^a   Boerman, O C ^a   Hendriks, T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LUTETIUM; MONOCLONAL ANTIBODY; PENTETIC ACID; RADIOISOTOPE;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; COLORECTAL TUMOR; COMPARATIVE STUDY; MALE; METHODOLOGY; RADIOIMMUNOTHERAPY; RAT; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; LUTETIUM; MALE; NEOPLASM TRANSPLANTATION; PENTETIC ACID; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RATS; TUMOR CELLS, CULTURED;

EID: 79251521820     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.7361     Document Type: Article

References (27)

1. Parkin DM,. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543.
2. Abulafi AM, Williams NS,. Local recurrence of colorectal cancer: the problem, mechanisms, management and adjuvant therapy. Br J Surg 1994; 81: 7-19.
3. Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J,. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 2006; 93: 1115-1122.
4. Burdy G, Panis Y, Alves A, Nemeth J, Lavergne-Slove A, Valleur P,. Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 2001; 44: 1682-1688.
5. Sjövall A, Granath F, Cedermark B, Glimelius B, Holm T,. Loco-regional recurrence from colon cancer: a population-based study. Ann Surg Oncol 2007; 14: 432-440.
6. Read TE, Mutch MG, Chang BW, McNevin MS, Fleshman JW, Birnbaum EH, et al., Locoregional recurrence and survival after curative resection of adenocarcinoma of the colon. J Am Coll Surg 2002; 195: 33-40.
7. Maggiori L, Elias D,. Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends. Eur J Surg Oncol 2010; 36: 599-603.
8. Behr TM, Salib AL, Liersch T, Béhé M, Angerstein C, Blumenthal RD, et al., Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study. Clin Cancer Res 1999; 5 (Suppl 10): 3232s-3242s. (Pubitemid 29493921)
9. Blumenthal RD, Sharkey RM, Natale AM, Kashi R, Wong G, Goldenberg DM,. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. Cancer Res 1994; 54: 142-151.
10. Koppe MJ, Hendriks T, Boerman OC, Oyen WJ, Bleichrodt RP,. Radioimmunotherapy is an effective adjuvant treatment modality after cytoreductive surgery of peritoneal carcinomatosis of colonic origin. J Nucl Med 2006; 47: 1867-1874.
11. Aarts F, Hendriks T, Boerman OC, Koppe MJ, Oyen WJ, Bleichrodt RP,. A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats. Ann Surg Oncol 2007; 14: 3274-3282.
12. Behr TM, Goldenberg DM, Becker WS,. Radioimmunotherapy of solid tumors: a review of mice and men. Hybridoma 1997; 16: 101-107.
13. de Jong GM, Boerman OC, Heskamp S, Aarts F, Bleichrodt RP, Hendriks T,. Radioimmunotherapy prevents local recurrence of colonic cancer in an experimental model. Br J Surg 2009; 96: 314-321.
14. Hagenaars M, Koelemij R, Ensink NG, van Eendenburg JD, van Vlierberghe RL, Eggermont AM, et al., The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma. Clin Exp Metastasis 2000; 18: 281-289.
15. Hagenaars M, Ensink NG, Basse PH, Hokland M, Nannmark U, Eggermont AM, et al., The microscopic anatomy of experimental rat CC531 colon tumour metastases: consequences for immunotherapy? Clin Exp Metastasis 2000; 18: 189-196.
16. Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, et al., Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med 2004; 45: 1224-1232.
17. Manekeller S, Sioutis M, Hirner A, Minor T,. [Influence of neoadjuvant chemotherapy on liver integrity and ischemic tolerance.] Z Gastroenterol 2008; 46: 17-21.
18. el-Malt M, Ceelen W, Van den Broecke C, Cuvelier C, Van Belle S, de Hemptinne B, et al., Influence of neo-adjuvant chemotherapy with 5-fluorouracil on colonic anastomotic healing: experimental study in rats. Acta Chir Belg 2003; 103: 309-314.
19. Holmes J, Stanko J, Varchenko M, Ding H, Madden VJ, Bagnell CR, et al., Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 1998; 46: 342-351.
20. Mahteme H, Larsson BS, Sundin A, Graf W,. 5-FU uptake in liver metastases after intravenous and intraperitoneal administration: an autoradiographic study in the rat. Anticancer Res 1998; 18: 943-949.
21. Chatal JF, Davodeau F, Cherel M, Barbet J,. Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors. J Cancer Res Ther 2009; 5 (Suppl 1): S36-S40.
22. Sharkey RM, Goldenberg DM,. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005; 46 (Suppl 1): 115S-127S.
23. Jain M, Venkatraman G, Batra SK,. Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Clin Cancer Res 2007; 13: 1374-1382.
24. Jain RK,. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990; 50 (Suppl 3): 814s-819s.
25. Couturier O, Supiot S, Degraef-Mougin M, Faivre-Chauvet A, Carlier T, Chatal JF, et al., Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging 2005; 32: 601-614.
26. DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, ODonoghue JA, Sgouros G, et al., Rationales, evidence, and design considerations for fractionated radio-immunotherapy. Cancer 2002; 94 (Suppl 4): 1332-1348.
27. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH,. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 2003; 44: 400-411.